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Historically, the control of renal vascular and tubular function has, for the most part, 
concentrated on neural and endocrine regulation. However, in addition to these extrinsic 
factors, it is now appreciated that several complex humoral control systems exist within 
the kidney that can act in an autocrine and/or paracrine fashion. These paracrine systems 
complement neuroendocrine regulation by dynamically tuning renal vascular and 
tubular function to buffer rapid changes in nephron perfusion and flow rate of tubular 
fluid. One of the most pervasive is the extracellular nucleotide/P2 receptor system, 
which is central to many of the intrinsic regulatory feedback loops within the kidney 
such as renal haemodynamic autoregulation and tubuloglomerular feedback (TGF). 
Although physiological actions of extracellular adenine nucleotides were reported 
almost 100 years ago, the conceptual framework for purinergic regulation of renal 
function owes much to the work of Geoffrey Burnstock. In this review, we reflect on 
our >20-year collaboration with Professor Burnstock and highlight the research that is 
still unlocking the potential of the renal purinergic system to understand and treat 
kidney disease.  
 
1. Introduction  
Forty years after the potent effects of adenine compounds on cardiac and smooth muscle 
were first shown1, the role of ATP as a non-adrenergic, non-cholinergic 
neurotransmitter was proposed and the term ‘purinergic’ coined2. Another five decades 
on and purinergic signalling has progressed from controversy to therapy, and is now a 
well-trodden path; the key role of Geoff Burnstock, who was in the vanguard and guided 
many of us along the way, is widely acknowledged and justly applauded. Our first 
contact with Geoff came in the early 1990s with an informal chat based on a shared 
interest in co-transmitters in the gut and their role in other organs, including potentially 
the kidney3. Geoff’s laboratory at the time was based in the Department of Anatomy on 
UCL’s main campus. His group had just begun cloning P2 receptors, an advance that 
provided improved molecular tools to allow detection and localisation of P2 receptors 
(P2R) in tissue samples. Tools for P2X1R were particularly good at that time and our 
collaboration began there. This led to the first comprehensive analysis of P2X1R 
expression in the kidney4, an auspicious beginning given the important role of this 
receptor in renal vascular physiology and disease, which is discussed more below. This 
was followed by a systematic analysis of P2YR in defined nephron segments5,6, 
painstakingly dissected from the rat kidney, and examination of renal nerves as a source 
of ATP to the glomerulus7. Thence, it was a short step to unravelling the functionality 
of P2R in physiology8 and disease9,10. 
In 2003, Unwin, Bailey and Burnstock published a ‘state-of-play’ review synthesising 
current knowledge of the renal purinergic system11, which at that time was largely 
descriptive and/or limited to cell models; potential was there but as yet unrealised. The 
literature has expanded enormously since then12,13 and the concept of renal purinergic 
signalling is so widely acknowledged as important that it has warranted a chapter in one 
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of the most influential textbooks on kidney function14. The Burnstock vision was to 
leverage knowledge of the purinergic system to treat human disease.  The research 
discussed here demonstrates that abnormal purinergic signalling can contribute to 
kidney disease and provides a platform for realising the therapeutic potential of this 
system.  
2. ATP in the Kidney 
Extracellular ATP is released as a paracrine/autocrine signal by many cells of the 
kidney and regulates various aspects of normal renal vascular and tubular physiology. 
Extracellular ATP is also recognised as a damage-associated molecular pattern 
(DAMP) signal involved in the  pathophysiology of some acute renal dieases, 
particularly as part of the inflammatory response to abrupt tissue injury and which 
depends on controlling local ATP concentrations15. ATP, UTP and UDP are released 
from intracellular storage pools to the extracellular compartment by multiple cell types 
under inflammatory or hypoxic conditions16. Although it is known that ATP release can 
occur in an uncontrolled fashion during processes leading to cell necrosis, studies have 
examined the molecular pathways involved in the controlled release of extracellular 
ATP. These studies have been reviewed in detail elsewhere17,18. Briefly. inflammatory 
cells can release ATP via pannexins or connexin hemichannels19,20. Pannexins, 
transmembrane protein channels, act to connect the extracellular and intracellular 
spaces, and are thought to be involved in the controlled release of ATP from apoptotic 
cells21. Connexins have also been suggested to control ATP release from inflammatory 
cells and the vascular endothelium following shear stress17.  
Extracellular ATP and UTP are rapidly degraded to ADP and UDP, respectively, by 
catabolic enzymes, the ectonucleotidases; these breakdown products are themselves 
potent agonists at P2Y1,6,12,13 and 14 receptors. ADP itself can be metabolised further 
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by CD39 (ENTPD1) to produce 5’-AMP, before the final step in ATP breakdown to 
produce adenosine by CD73 (NT5E). As shown in Figure 1, P1 receptors recognize 
adenosine, while P2R bind di- and tri-phosphate nucleotide molecules.  
ATP has been shown to have a role in the regulation of many processes fundamental to 
the integrated control of salt and volume homeostasis, renal autoregulation22,23 
tubuloglomerular feedback (TGF)24,25 and epithelial solute transport in most nephron 
segments26. An important aspect is that ATP release is induced by physiological stimuli 
such as increased luminal flow27, and ATP/P2 signalling emerges as a core aspect of 
the instrinsic renal feedback loops that influence higher order physiology. Thus, sensing 
of NaCl by the macula densa is the afferent arm of TGF: as delivery increases, macula 
densa cells swell and release ATP basolaterally as the primary effector molecule. It has 
been estimated that ATP concentration at the basolateral surface of the macula densa 
acn approach 10 μmol/L28. Even when considering the rapid nature of ATP 
catabolism15, concentrations in the 10 μmol/L range would be expected to be sufficient 
to engage a significant physiological response.   
ATP also emerges as an important effector molecule for the pressure natriuresis 
response, the physiological process by which increased arterial pressure induces sodium 
excretion to regulate extracellular fluid volume and exert long-term blood pressure 
control15. Pressure natriuresis is also mechanically initiated phenomenon with ATP at 
its core. Using microdialysis techniques Navar et al demonstrated a positive relationship 
between renal artery perfusion pressure (RPP) and ATP concentrations in the medullary 
interstitium29–31. This relationship was confirmed using ATP sensors to detect tissue 
levels of ATP in real-time and show a dynamic response to alterations in RPP that 
correlated with the ensuing natriuresis32. The blunting of pressure natriuresis in 
connexin30 knockout mice confirms that the release of ATP from renal cells is an 
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important part of the response33.  A study published in 2020 using microdialysis 
techniques also demonstrated a positive correlation between the autoregulatory and 
TGF-mediated adjustments in renal vascular resistance and renal interstitial ATP 
concentrations, suggesting that autoregulation-dependent changes in renal vascular 
resistance are mediated by corresponding changes in interstitial ATP concentrations34. 
3. P2 Receptors in the kidney  
Within the kidney, purinergic signalling in both renal physiology and pathophysiology 
is an expanding area of research. In normal physiology, P2R have been shown to be 
expressed in almost all segments of the nephron, vasculature and interstitial cells, while 
differential basolateral and apical cell membrane expression of P2R has also been 
reported5,6 (Figure 2).  P2R have been shown to be functionally expressed on both 
inflammatory cells and structural cells of the kidney, including mesangial cells and 
podocytes12,35. P2R activation on these cell types is thought to result in a range of 
cellular responses, including cell migration, release of chemokines or cytokines, 
production of reactive oxygen species, induction of apoptosis, and chloride 
secretion12,18,36,37.  
3.1 Vasculature  
P2R are expressed across the kidney macro- and micro-vasculature and have been 
shown to have a strong influence on vascular function38. P2R subunit expression and 
localisation in relation to renal vascular and microvascular function has been discussed 
in detail elsewhere39. It is noteworthy that P2X1R has been identified in the vascular 
smooth muscle of the rat renal, arcuate and interlobular arteries, and in the afferent 
arteriole; P2X2R in the smooth muscle of larger renal arteries, and P2X4R in the 
vascular endothelium12. Moreover, P2X7R mRNA has been shown to be expressed 
under normal, non-inflammatory conditions in endothelial cells40,41 and this receptor 
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has been immunolocalized to the endothelium of the pre-glomerular vasculature42, and 
also shown to be expressed in the vasa recta43 with functional data suggesting its 
activation results in contraction of renal medullary pericytes44.  
P2Y12R have been found to be highly expressed by platelets and have an established 
role in platelet activation, which has become a target for newer antiplatelet therapies 
such as clopidogrel and ticagrelor45. However P2Y12R has also been detected in both 
human and rat non-renal vascular tissue, and its expression in the cortex and outer and 
inner medulla in the vasculature and tubules46. It has been suggested that P2Y12R may 
have a role in controlling renal vessel tone and in tubular transport46,47. A recent study 
in vivo found that ADP can cause systemic and renal vasodilation, resulting in decreased 
mean arterial pressure, and determined that this effect was mediated partially by 
P2Y12R. It has been reported that P2Y12R also exert a tonic action to reduce tubular 
water reabsorption and thereby urinary concentrating ability48. Work by Kishore and 
colleagues localised P2Y12R at the protein level to the renal collecting duct, along with 
aquaporin-2. They found subsequently that administration of clopidogrel bisulphate, an 
irreversible inhibitor of P2Y12R, significantly increased urinary concentration and 
aquaporin-2 protein levels in the kidneys of Sprague-Dawley rats46. These findings led 
to the Kirshore group proposing that this mechanism might be important in the 
pathophysiology of cyst expansion in renal cystics diseases such as PKD.  
In relation to renal pathophysiology, abnormalities in the P2R system are known to be 
involved in renal diseases39, including diabetic nephropathy49. Long‐term blood 
pressure regulation is reliant on normal renal function50 making the P2 system an 
attractive field of hypertension research43.  
The P2R family is known to have a role in key regulatory processes within the kidney 
that, if disrupted, can have significant effects on renal function. Autoregulation, a vital 
 8 
process in the kidney, is known to be mediated by P2X1R in the kidney. Increased renal 
blood flow due to an increase in systemic blood pressure is buffered by P2X1-mediated 
vasoconstriction in the afferent arteriole, which protects the glomerulus from pressure-
induced injury. This is supported by work in P2X1R null mice that have been shown to 
have an attenuated pressure-induced vasoconstriction, resulting in autoregulatory 
failure and subsequent barotrauma51.  
P2X4R, the most abundantly expressed P2R in the vascular endothelium52, is activated 
by ATP and reinforces the normal vascular vasodilatory response to shear stress53. 
P2X4R knockout mice are hypertensive and show impaired endothelial production of 
nitric oxide (NO) following an increase in blood flow54. The impaired pressure 
natriuresis response as a result of the defect in NO production ultimately affects blood 
pressure control50.  
P2X7R expression and activity correlates with glomerular injury when present on 
glomerular cells, including infiltrating inflammatory cells, and in models of severe 
hypertension and type 1 diabetes10. It has been shown that expression of P2X7R is 
upregulated in glomerular disease and in a model of acute glomerulonephritis55, and 
that P2X7R-deficiency or blockade can attenuate renal injury in the experimental 
model56.   
3.2 Renal Tubules  
The distribution of P2 receptors along the tubules and the inhibitory effect on tubular 
electrolyte transport have been reviewed in depth12 and are summarised in Figure 239,57–
59. One of the best-established examples of intrarenal purinergic signalling is 
communication between tubule epithelial cells and vascular smooth muscle cells of the 
afferent arteriole to achieve TGF, the co-ordination of glomerular filtration rate and 
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tubular transport within a single nephron58. An increase in distal tubular sodium 
chloride load results in basolateral ATP release from macula densa cells60 and the 
concentration of ATP in the cortical interstitium responds appropriately to inhibit or 
activate of TGF in vivo61. In most species, the macula densa is anatomically separated 
from the afferent arteriole by the extraglomerular mesangium. Thus, macula densa-
derived  ATP activates P2R to propogate a wave of calcium through the mesangium62. 
This ultimately results in afferent arteriolar constriction, engaging TGF. The release of 
ATP from mesangial cells and its hydrolysis to adenosine is suggested  by experiments 
in knockout mice that show a blunted TGF response in mice lacking either adenosine 
A1 receptors63 or ecto-5'-nucleotidase64. 
P2R act in a dual fashion to modulate ion transport. Secretory epithelia P2R are known 
to stimulate ion and water secretion, as opposed to absorptive epithelia, where P2R act 
to inhibit reabsorption65. As such, P2R stimulation can result in an increase or decrease 
in fluid secretion, with differing roles along the nephron. In the proximal tubule, P2Y1R 
in the luminal membrane inhibit HCO3 absorption66. In the distal convoluted tubule, 
luminal nucleotides inhibit TRPV5-dependent Ca2+ absorption67. In the cortical 
collecting duct, luminal and basolateral nucleotides inhibit ROMK-dependent K+ 
secretion68 and ENaC-dependent Na+ transport65. In the inner medullary collecting duct, 
basolateral nucleotides reduce aquaporin-2-dependent water transport69. More recently, 
use of designer receptors exclusively activated by designer drug (DREADD) 
technology in the renal tubule demonstrated that selective activation of the 
P2Y2 receptor and Gq signaling in principal cells of the collecting duct is sufficient to 
promote renal salt excretion70. 
Furthermore, recent work has suggested a role for tubular P2R and inflammasome 
signalling. Work by Lee et al. indicated that induction of kidney NLR family pyrin 
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domain containing 3 (NLRP3) inflammasome signalling after renal ischemia and 
reperfusion injury was significantly attenuated in P2X4 KO mice. A P2R agonist 
ATPγS can increase NLRP3 inflammasome signalling in isolated renal proximal tubule 
cells from WT mice; however, this was not observed in renal proximal tubules isolated 
from P2X4R knockout mice. Their findings suggested that renal proximal tubular 
P2X4R activation exacerbates ischemic acute kidney injury (AKI) and promotes 
NLRP3 inflammasome signalling71. 
4. P2 Signalling in Renal Disease.  
4.1 Immune Function and Inflammation  
Sustained tubule-interstitial inflammation has a key role in the development and 
progression of kidney disease by driving  a vicious cycle of injury, fibrosis, and 
impaired functionality (e.g., reduced GFR and impaired pressure natriuresis 
response72). A growing literature suggests that ATP and other purine and pyrimidine 
nucleotides contribute to triggerng and/or sustaining inflammation in acute and chronic 
renal disease73,74 by acting as ubiquitous and efficient DAMPs75 that can activate the 
innate immune response21. Indeed, purinergic signalling is intimately involved in 
activation of the NLRP3 inflammasome in the kidney, leading to production of the pro-
inflammatory cytokines IL-1β and IL-18, as well as pro-inflammatory cell death, 
pyroptosis76. 77. A variety of insults, toxic and ischemic, induce renal macrophages to 
release ATP, leading to autocrine activation of P2X7R to stimulate the NLRP3 
inflammasome and release IL-1β78,79. P2X7R can also stimulate inflammasome 
activation in a paracrine manner in response to ATP released following hypoxic injury 
with activation of P2X7R also having the potential to amplify ATP release from 
macrophages80,81. The role of inflammation mediated by the NLRP3 inflammasome in 
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the progression of CKD and its potential as a therapeutic target is an area of intense 
research interest at present and is considered elsewhere82. 
Approaches targeting the purinergic system are proving effective in pre-clinical models 
of acute and chronic renal diseases. Thus, P2X7R blockade (or P2X7R deficiency in 
hematopoietic cells) ameliorated renal ischemic reperfusion injury in mice due to the 
expansion of regulatory T-cells83. Apyrase treatment to scavenge extracellular ATP is 
similarly protective84.  In a rat transplant model, oxidised ATP, which blocks P2X7R, 
protects against acute kidney allograft rejection by suppression of T cell, B cell and 
macrophage activity85.  However, to sound a more cautionary note, P2 receptors are 
expressed in various immune cells (eosinophils, neutrophils, mast cells, 
monocytes/macrophages, and lymphocytes86) and extracellular nucleotides ican 
nfluence a wide number of diverse inflammatory reactions. These action are complex, 
and often reciprocal. In macrophages, for example, ATP/P2X7 signalling has the 
capacity to polarise cells into either a pro-inflammation or pro-resolution phenotype87. 
Therefore, the role purinergic signalling in progressive renal disease is not fully 
elucidated and the likely therepeutic potential of this system is not yet apparent.   
4.2 Diabetic Kidney Disease (DKD) 
DKD is the leading cause of renal failure88 and incorporates aspects of chronic 
inflammation, fibrosis and remodelling with functional decline. Unsurprisingly, 
abnormal purinergic signalling has long been considered a contributory factor in the 
progression of DKD. Two major contributory pathways emerge from a large literature. 
First, diabetes reduces beneficial P1 receptor activation by adenosine; second, 
augmented extracellular ATP activates an over-expressed renal P2X7 receptor35. 
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The role of the P1 receptor system in diabetes is discussed elsewhere89. This system is 
consider “beneficial” because of antithromboic and anrti-inflammatory actions of P1 
activation. An important additional aspect in kidney functionality is the tonic 
suppression of single nephron GFR by A1 and A2A receptor activation90. Activation of 
A1R in the afferent arteriole normally leads to vasoconstriction, reducing capillary 
hydrostatic pressure and lowering single nephron GFR. In diabetes, A1R knockout mice 
have an exaggerated glomerular hyperfiltration, an early hallmark of DKD and 
ultimately develop more severe nephropathy91. Similarly, activation of A2AR causes 
vasodilation of the efferent arteriole, also reducing hydrostatic pressure in the 
glomerular capillaries and acting as a brake on single nephron GFR. In diabetic rats, 
this tonic control system is attenuated, contributing to glomerular hyperfiltration, an 
early feature of DN. Mechanistically, this mostly likely reflects reduced levels of 
ambient adenosine, since administration of CGS21680, an A2AR agonist, lowered 
single nephron GFR in diabetic animals92, at least acutely. Chronic administration of 
CGS21680 also improved other hallmarks of DN, reducing proteinuria and levels of 
renal pro-inflammatory cytokines93. Such studies posit the hypothesis that diabetes 
attenuates adenosine/P1 signalling within key compartments of the kidney, perhaps by 
attenuating the activity of CD39, the pivot point controlling the balance between local 
P2 and P1 activation. Is there evidence to support this? CD39 knockout mice display 
more severe DN than wild-type controls94; CD39 overexpression protects against 
diabetes incidence in mice95.  In humans, polymorphisms in ENTPD1, the gene 
encoding CD39, are associated with altered risk from DKD in African Americans with 
type 2 diabetes96. However, when assessed in cell lines, risk haplotypes increased, and 
protective haplotypes reduced CD39 expression96. This runs counter to the hypothesis 
but loss of CD39 seems to improve global metabolic phenotype in both mice and 
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humans. Thus, actions of CD39 differ between physiological systems and this adds a 
layer of complexity when trying to assess whether the CD39/adenosine/P1 cascade is 
therapeutically tractable in DKD.  
The otherside of this coin is an intrarenal environment with sustained elevations in 
extracellular ATP, with important ramifications for P2R signalling. We previously 
examined renal biopsy sections from type 2 diabetics and immunolocalized P2X7R to 
glomeruli or glomerular mesangium. P2X7R was not expressed in non-diabetic control 
biopsies. Receptor activation amplified the release of MCP-1 (monocyte 
chemoattractant protein-1; aka CCL2) by human mesangial cells cultured in 
hyperglycaemic conditions49. This is important because enhanced mesangial secretion 
of MCP-1 results in macrophage accumulation and glomerular injury97, which 
ultimately leads to the development of glomerular scarring and fibrosis. Indeed, 
elevated urinary MCP-1 to creatinine ratio has been shown to predict renal decline98. 
Whether therapeutic P2X7R antagonism can reverse DKD is unclear, but early 
experiments are encouraging: P2X7R knockout mice are protected from type 1 diabetes, 
having fewer macrophages infiltrating the glomerulus and reduced collagen IV 
deposition49. Encouraging research also comes from the diabetic rat, which identified a 
potentially adverse interaction between renal P2X7R and klotho, a membrane-bound 
protein with antioxidant and antiapoptotic properties, which is reduced in all forms 
chronic kidney disease99. An siRNA targeting P2X7R was shown to be have a beneficial 
on the kidneys of the streptozotocin rat model of type 1 diabetes to increase renal klotho 





Genetic studies identify associations between single-nucleotide polymorphisms in 
genes encoding P2X4R (the loss of function variant rs28360472)101 and P2X7R 
(intronic variant rs591874)102 with incressed blood pressure. Animal studies, by us and 
others have provided some mechanistic insights using ANG-II-dependent hypertension 
as the experimental model. In this setting, Brilliant Blue G, a non-selective inhibitor of 
P2X4R and P2X7R restored the impaired pressure natriuresis response in the model 
and acutely lowered blood pressure42. Renal medullar perfusion and oxygenation were 
also acutely increased by the highly selective P2X7R antagonist AZ1165731244. In a 
series of elegant experiments, Franco and colleagues showed that chronic ANG-II 
induced renal over-expression of P2X1R, P2X7R, and P2X4R and provided direct 
evidence that acute blockade of P2X1R or P2X7R, but not P2X4R, increased single 
nephron GFR103. The effects of P2X1R, P2X7R, and AT1R actions converge at receptor 
and/or post-receptor signalling pathways, but purinergic signalling exerts the dominant 
influence on arteriolar resistance in ANG-II-dependent hypertension104.  
These acute studies indicate that P2R antagonism, particularly P2X1R and P2X7R, can 
improve physiological end-points in experimental hypertension. The translational 
potential is supported by studies showing that prophylactic P2X7R antagonism or 
‘knock-out’ of the murine P2X7k transcript lowers blood pressure and protects against 
the injury associated with experimental hypertension105,106; some of the anti-
inflammatory effects of P2R antagonism such as reduced renal immune cell infiltration 
and the levels of NLPR3 activation appear to be independent of reduced blood 
pressure107.  
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The overall picture that emerges is that a sustained increase in arterial pressure enhances 
ambient ATP levels in the renal interstitium that activate purinergic P2X1R and P2X7R 
and promote a cascade of immune cell infiltration, inflammation and  renal macro- and 
microvascular dysfunction.   
4.4 Polycystic Kidney Disease (PKD) 
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common 
inherited nephropathy and the fourth most common cause of renal failure in the Western 
world108. In a rat model of ADPKD, expression levels of P2X7R, P2Y2R and P2Y6R 
were found to be increased in the cystic epithelia and influence cyst growth109. 
Furthermore, epithelial cells from patients with ADPKD have been found to release 
higher levels of ATP when compared with healthy controls110. A further study noted 
increased levels of ATP within cyst fluid. This may reflect increased secretion from 
cells, but notably CD39 expression is also reduced in ADPKD patients111, suggesting 
extracellular hydrolysis is impaired, prolonging P2R signalling. Finally, in a P2X7R 
KO zebrafish model, a reduction in cyst formation was noted. These findings suggest 
that P2X7R antagonism may have the potential as a drug target in the treatment of 
ADPKD112. This was shown more recently in a rat model in which findings indicated 
that P2X7R contributes to cyst growth by increasing pannexin-1-dependent pathogenic 
ATP release into the cyst lumen and a reduction in sodium transport across the cyst 
wall113. Similarly, in a mouse model of ADPKD both P2X7R and pannexin-1 were 
found to be abnormally increased in cyst lining cells compared with non-dilated 
collecting ducts. The authors also measured luminal accumulation of ATP in M1 cell 
renal collecting duct monolayers following treatment with the uricosuric drug 
probenecid, which is also a Panx1 antagonist. Their findings indicate that blockade of 
Panx1 can prevent release of ATP. These authors suggested that in the progression of 
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ADPKD, abnormally increased expression of both PANX1 and P2RX7 occurs in cyst 
lining epithelial cells, resulting in a pannexin1/P2X7R cooperation that leads to 
increased ATP release into the cyst luminal: high ATP levels are a consistently in 
association with cystogenesis. 
5. Conclusion 
Extracellular ATP and its metabolite adenosine are powerful signalling molecules that 
activate P2 or P1 purinergic receptors, respectively. Activation of purinergic receptors 
triggers multiple cascades, eliciting varied biological functions in the kidney and this 
processs has been shown to be dysregulated under pathophysiological conditions. There 
is strong pre-clinical data for targeting the purinergic system in renal disease. However, 
most approaches employ either knockout or prophylactic pharmacological strategies 
that, in the main, do not reflect the reality of clinical management of established renal 
disease. Similarly, it is increasinglty evident that genetic variants in P2 receptors, 
including P2X7R, are important experimental considerations. The pharmacogenomics 
of receptors and the impact of this on treatment to reduce disease progression is largely 
unexplored and a further obstacle to rapid clinical translation.  Nevertheless, the pre-
clinical studies do add value and we are beginning to gain a clearer picture of how the 
purinergic system operates in health and disease. The next phase of research will be to 
enhance our modelling of human disease, either with more chronic paradigms or using 
humanised models, including organoids and integrated microsystems to define key 
biological processes and provide a better understanding of how isoform-specific 
receptor antagonists can be be deployed in kidney disease. Our esteemed colleague and 
mentor, Professor Geoffrey Burnstock would, we are sure, agree with this and push us 
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Figure 1: The autocrine / paracrine purinoceptor system. In the kidney ATP release into 
the extracellular space is triggered by a range of stimuli including cellular stretch 
(sensing increase blood flow and renal tubular fluid flow), trauma, or agonist 
binding. Ectonucleotidases located on the plasma membrane catalyse sequential 
hydrolysis of ATP to ADP, 5’AMP and adenosine. P1 receptors recognize 
adenosine while P2 receptors bind di- and tri-phosphate nucleotide molecules. 
P2X receptors are non-selective cation channels with 3 protein subunits which 
may form homo- or heteromeric arrangements; all bind ATP. P2Y receptors are 
7 transmembrane-spanning domain G-protein-coupled receptors; agonist 
preferences span adenosine and uracil di- and tri- nucleotides. NTPDase: 
ectonucleoside triphosphate diphosphohydrolase. 
 
Figure 2: P2 Receptors in the kidney. P2Y and P2X receptor expression in the renal 
vasculature, glomeruli and tubules. 
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